Vcanbio Cell & Gene Engineering Corp., Ltd

Total Valuation

Vcanbio Cell & Gene Engineering Corp., Ltd carries a market capitalization of 8.85B, placing it among publicly traded companies globally. Its enterprise value stands at 13.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Vcanbio Cell & Gene Engineering Corp., Ltd currently has 467.95M shares outstanding.

Valuation Ratios

Vcanbio Cell & Gene Engineering Corp., Ltd trades at a trailing price-to-earnings ratio of 250.10. The price-to-sales ratio is 14.33, and the price-to-book ratio stands at 38.52.

Enterprise Valuation

On an enterprise value basis, Vcanbio Cell & Gene Engineering Corp., Ltd trades at an EV/EBITDA multiple of 102.06 and an EV/FCF ratio of 398.46. The EV/Sales ratio of 12.79 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 102.06 provides insight into valuation relative to core operating earnings.

Financial Position

Vcanbio Cell & Gene Engineering Corp., Ltd maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Vcanbio Cell & Gene Engineering Corp., Ltd posts a return on equity of 17.94 and a return on invested capital of 1.67.

Taxes

Over the trailing twelve months, Vcanbio Cell & Gene Engineering Corp., Ltd has paid 56.75M in income taxes, reflecting an effective tax rate of 50.99.

Stock Price Statistics

Vcanbio Cell & Gene Engineering Corp., Ltd's stock has declined approximately -24.50485% over the past 52 weeks. The 50-day moving average sits at 21.15, while the 200-day moving average is 25.46.

Income Statement

Over the trailing twelve months, Vcanbio Cell & Gene Engineering Corp., Ltd generated 1.05B in revenue and converted that into 59.91M in net income, yielding earnings per share of 0.11. EBITDA reached 131.01M, while operating income came in at 131.01M.

Balance Sheet

Vcanbio Cell & Gene Engineering Corp., Ltd holds 1.73B in cash and equivalents against 74.32M in total debt, resulting in a net debt position of -1.58B. Total book value stands at 388.94M, with working capital of 1.25B providing operational flexibility.

Cash Flow

After subtracting -33.56M in capital expenditures, free cash flow totaled -33.56M - equivalent to -0.07 per share.

Margins

Vcanbio Cell & Gene Engineering Corp., Ltd operates with a gross margin of 70.14, reflecting its pricing power and cost economics. The operating margin of 12.53 and net profit margin of 5.73 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Vcanbio Cell & Gene Engineering Corp., Ltd's most recent stock split took place on January 24, 2007 with a 10000:16983 split ratio.

Scores

Vcanbio Cell & Gene Engineering Corp., Ltd posts an Altman Z-Score of 6.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.